XFOR - X4 Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
17.32
-0.32 (-1.81%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close17.64
Open17.49
Bid15.90 x 800
Ask18.42 x 800
Day's Range17.07 - 18.03
52 Week Range6.90 - 114.00
Volume16,675
Avg. Volume54,895
Market Cap215.128M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.90
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • Business Wire10 days ago

    X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and The Leukemia & Lymphoma Society (LLS) today announced a collaboration to accelerate the development of X4’s lead product candidate, mavorixafor (X4P-001) for the treatment of Waldenström’s macroglobulinemia (WM), a rare form of non-Hodgkin lymphoma.

  • Business Wirelast month

    X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of E. Lynne Kelley, M.D., FACS, as the company’s Chief Medical Officer (CMO). Dr. Kelley brings more than a decade of experience driving clinical development and global expansion of novel pharmaceutical products at both emerging and established life sciences companies.

  • Business Wirelast month

    X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 5,670,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 2,130,000 shares of common stock, and accompanying Class A warrants to purchase 3,900,000 shares of its common stock at a price to the public of $11.00 per share and accompanying Class A warrant (or $10.999 per pre-funded warrant and accompanying Class A warrant). X4’s gross proceeds from this offering are expected to be approximately $85.8 million, before deducting underwriting discounts and estimated offering expenses.

  • Business Wirelast month

    X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Class A warrants to purchase its common stock. All of the securities in the offering will be sold by X4.

  • Business Wire2 months ago

    X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Murray Stewart, M.D., as an independent member of the X4 Board of Directors. “We’re very pleased to welcome Dr. Stewart to the X4 Board,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.

  • Business Wire2 months ago

    X4 Pharmaceuticals Provides Business and Clinical Development Update

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today provided a business and clinical development update. “This has been a transformative period for X4 with our listing on Nasdaq, finalization of our Phase 3 clinical protocol in WHIM syndrome and the recent approval from the WHO for the use of mavorixafor as our lead candidate name for X4P-001,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.